| Acetyl-CoA and the regulation of metabolism: mechanisms and consequences L Shi, BP Tu Current opinion in cell biology 33, 125-131, 2015 | 872 | 2015 |
| TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ... Cancer discovery 9 (8), 1064-1079, 2019 | 337 | 2019 |
| Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma SK Saha, JD Gordan, BP Kleinstiver, P Vu, MS Najem, JC Yeo, L Shi, ... Cancer discovery 6 (7), 727-739, 2016 | 167 | 2016 |
| Trehalose is a key determinant of the quiescent metabolic state that fuels cell cycle progression upon return to growth L Shi, BM Sutter, X Ye, BP Tu Molecular biology of the cell 21 (12), 1982-1990, 2010 | 162 | 2010 |
| Acetyl-CoA induces transcription of the key G1 cyclin CLN3 to promote entry into the cell division cycle in Saccharomyces cerevisiae L Shi, B Tu PNAS 110 (18), 7318-7323, 2013 | 161 | 2013 |
| Mutant IDH inhibits IFNγ–TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma MJ Wu, L Shi, J Dubrot, J Merritt, V Vijay, TY Wei, E Kessler, KE Olander, ... Cancer discovery 12 (3), 812-835, 2022 | 107 | 2022 |
| Cycloheximide can distort measurements of mRNA levels and translation efficiency DA Santos, L Shi, BP Tu, JS Weissman Nucleic acids research 47 (10), 4974-4985, 2019 | 89 | 2019 |
| Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway J Zhang, CM Simpson, J Berner, HB Chong, J Fang, Z Ordulu, ... Cell 186 (11), 2361-2379. e25, 2023 | 88 | 2023 |
| NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer T Weiss-Sadan, M Ge, M Hayashi, M Gohar, CH Yao, A de Groot, S Harry, ... Cell metabolism 35 (3), 487-503. e7, 2023 | 84 | 2023 |
| FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma JM Cleary, S Raghavan, Q Wu, YY Li, LF Spurr, HV Gupta, DA Rubinson, ... Cancer discovery 11 (10), 2488-2505, 2021 | 78 | 2021 |
| EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion–positive cholangiocarcinoma Q Wu, Y Zhen, L Shi, P Vu, P Greninger, R Adil, J Merritt, R Egan, MJ Wu, ... Cancer discovery 12 (5), 1378-1395, 2022 | 73 | 2022 |
| Cycling transcriptional networks optimize energy utilization on a genome scale GZ Wang, SL Hickey, L Shi, HC Huang, P Nakashe, N Koike, BP Tu, ... Cell reports 13 (9), 1868-1880, 2015 | 65 | 2015 |
| Protein acetylation as a means to regulate protein function in tune with metabolic state L Shi, B Tu Biochemical Society Transactions 42 (4), 1037-1042, 2014 | 52 | 2014 |
| Npr2 inhibits TORC1 to prevent inappropriate utilization of glutamine for biosynthesis of nitrogen-containing metabolites S Laxman, BM Sutter, L Shi, BP Tu Science signaling 7 (356), ra120-ra120, 2014 | 51 | 2014 |
| Biology of IDH mutant cholangiocarcinoma MJ Wu, L Shi, J Merritt, AX Zhu, N Bardeesy Hepatology 75 (5), 1322-1337, 2022 | 47 | 2022 |
| Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016; 6: 727–739. doi: 10.1158/2159-8290 SK Saha, JD Gordan, BP Kleinstiver, P Vu, MS Najem, JC Yeo, L Shi, ... CD-15-1442, 0 | 27 | |
| DrugMap: A quantitative pan-cancer analysis of cysteine ligandability M Takahashi, HB Chong, S Zhang, TY Yang, MJ Lazarov, S Harry, ... Cell 187 (10), 2536-2556. e30, 2024 | 23 | 2024 |
| GATOR1 regulates nitrogenic cataplerotic reactions of the mitochondrial TCA cycle J Chen, BM Sutter, L Shi, BP Tu Nature chemical biology 13 (11), 1179-1186, 2017 | 21 | 2017 |
| Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity MJ Wu, H Kondo, AV Kammula, L Shi, Y Xiao, S Dhiab, Q Xu, CJ Slater, ... Science 385 (6705), eadl6173, 2024 | 16 | 2024 |
| FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 2021 … JM Cleary, S Raghavan, Q Wu, YY Li, LF Spurr, HV Gupta, DA Rubinson, ... DOI: https://doi. org/10.1158/2159-8290. CD-20-1669, 2488-2505, 0 | 15 | |
Sunil LaxmanInstitute for Stem Cell Science and Regenerative Medicine (inStem), UTSW, U WashingtonПотвърден имейл адрес: instem.res.in